New combo aims to tame tough kidney cancer
NCT ID NCT06284564
First seen Nov 01, 2025 · Last updated May 07, 2026 · Updated 25 times
Summary
This study tests whether adding evolocumab to the immunotherapy drug nivolumab can help control metastatic renal cell carcinoma that has not responded to prior treatments. Ten adults with clear-cell kidney cancer will receive the combination, and researchers will monitor safety and side effects. The goal is to improve disease control, not to cure the cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC RENAL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
UT Southwestern Medical Center
Dallas, Texas, 75390, United States
Conditions
Explore the condition pages connected to this study.